Manfredi Roberto
Dipartimento di Medicina Clinica Specialistica e Sperimentale, Sezione di Malattie Infettive, Università degli Studi di Bologna Alma Mater Studiorum, Azienda Ospedaliera di Bologna, Policlinico S. Orsola-Malpighi, Bologna.
Recenti Prog Med. 2003 Apr;94(4):149-53.
Both HIV disease and chronic HBV and HCV hepatitis recently benefited by significantly improved combination antiviral treatments, which, led to a remarkably increased life expectancy, and reduced morbidity and mortality rates of these potentially life-threatening disorders. However, many problems still wait definite solutions. Among them, the liver toxicity expected from administration of complex antiviral regimens (especially when co-infection is of concern), potential drug-drug interactions, the still unknown pathogenetic connections with the broad spectrum of metabolic abnormalities complicating long-term antiretroviral treatment, and the expected outcome of these issues on clinical management, therapeutic monitoring, and disease prognosis.
